Event Details
Dates: August 18–20, 2025
Location: Capital Hilton, 1001 16th St NW, Washington, DC 20036
Event Website: https://www.nextgenerationdx.com
About the Event
Cizzle Bio is attending the 17th Annual Next Generation Dx Summit, taking place in Washington, D.C. from August 18–20, 2025. Hosted by the Cambridge Healthtech Institute, this summit brings together global leaders across diagnostics, regulatory, and research sectors to explore the latest breakthroughs in liquid biopsy, point-of-care testing, early cancer detection, and clinical validation.
As part of our mission to make early cancer detection more accessible, accurate, and minimally invasive, we are joining this year’s summit to learn, connect, and engage with peers shaping the future of diagnostics.
Why We’re Attending
Cizzle Bio is focused on transforming the diagnostic pathway with biomarker-based blood tests that detect cancer early—when treatment is most effective. Events like Next Generation Dx offer a vital opportunity to:
Stay informed on the latest advancements in liquid biopsy, MCED, and companion diagnostics
Learn from expert discussions on regulatory trends, AI integration, and real-world validation
Explore how innovative companies and institutions are addressing barriers to equitable cancer screening
Connect with fellow innovators, payers, and research partners dedicated to improving patient outcomes
About the Summit
The Next Generation Dx Summit features 12+ tracks covering the most urgent topics in diagnostics, including:
Multi-cancer early detection and guidance on diagnostic workups following MCED results
AI and machine learning in IVD development
Regulatory updates from CMS, NIH, and industry leaders
Reimbursement strategies for advanced diagnostics
Liquid biopsy innovations for early detection and disease monitoring
Interactive roundtables with experts from NIH, MD Anderson, Beckman Coulter, and more
As diagnostic innovation accelerates, Cizzle Bio remains committed to contributing meaningfully to this ecosystem—with science that supports clinical utility, promotes equity in access, and enables earlier intervention through simple blood tests.